Birgit Girshick Sells 6,500 Shares of Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) CEO Birgit Girshick sold 6,500 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the completion of the sale, the chief executive officer directly owned 36,013 shares of the company’s stock, valued at approximately $10,080,038.70. This trade represents a 15.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Down 0.6%

Shares of CRL stock opened at $279.70 on Friday. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. Charles River Laboratories International, Inc. has a one year low of $144.26 and a one year high of $288.02. The company’s fifty day moving average price is $224.87 and its 200-day moving average price is $191.33. The company has a market capitalization of $13.35 billion, a price-to-earnings ratio of -57.67, a PEG ratio of 2.92 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. During the same quarter in the prior year, the firm posted $3.12 EPS. Charles River Laboratories International’s quarterly revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CRL has been the subject of several research analyst reports. Piper Sandler set a $300.00 target price on Charles River Laboratories International in a research report on Monday. CLSA cut Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a report on Monday, July 20th. Evercore restated an “outperform” rating on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Royal Bank Of Canada increased their price objective on shares of Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Finally, BNP Paribas Exane set a $250.00 price objective on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $255.65.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Invesco Ltd. lifted its position in shares of Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after buying an additional 1,446,972 shares in the last quarter. Victory Capital Management Inc. grew its holdings in Charles River Laboratories International by 9,938.8% during the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock valued at $137,935,000 after buying an additional 684,586 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in Charles River Laboratories International by 1,491.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock valued at $96,005,000 after buying an additional 575,039 shares in the last quarter. Amundi increased its stake in Charles River Laboratories International by 175.2% in the 1st quarter. Amundi now owns 773,315 shares of the medical research company’s stock worth $133,397,000 after acquiring an additional 492,301 shares during the last quarter. Finally, Norges Bank bought a new stake in Charles River Laboratories International in the 4th quarter worth approximately $96,765,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.